NEW YORK, December 31, 2013 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Medtronic, Inc. (NYSE: MDT), Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), and MannKind Corp. (NASDAQ: MNKD). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Medtronic, Inc. Research Report
On December 17, 2013, Medtronic, Inc. (Medtronic) reported that the first patients were randomized in SYMPLICITY HTN-4, evaluating the Symplicity(TM) renal denervation system in patients with moderate uncontrolled hypertension (systolic blood pressure greater than or equal to 140 and less than 160 mm Hg, despite treatment with three or more anti-hypertensive medications of different classes). According to the Company, SYMPLICITY HTN-4 will enroll up to 580 patients with systolic blood pressures greater than or equal to 140 and less than 160 mm Hg at approximately 100 sites, continuing to target a patient population in line with the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC-7), the American Heart Association and the European Society of Hypertension's definition of uncontrolled hypertension. Nina Goodheart, Vice President, General Manager, Renal Denervation, Medtronic, commented, "SYMPLICITY HTN-4 demonstrates Medtronic's commitment to providing randomized safety and efficacy data for renal denervation in a wide variety of patients, as well as helping increase our understanding of the potential benefit of renal denervation for more patients with treatment resistant hypertension." The Full Research Report on Medtronic, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Regeneron Pharmaceuticals, Inc. Research Report
On December 19, 2013, Regeneron Pharmaceuticals, Inc. (Regeneron) and Sanofi jointly announced an innovative collaboration with the American College of Cardiology (ACC) that aims to improve clinical research with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), co-developed by Sanofi and Regeneron. According to the Company, PCSK9 is known to contribute to circulating low-density lipoprotein cholesterol (LDL-C) levels. Ralph Brindis, past-President of the ACC and Senior Medical Officer of External Affairs for the National Cardiovascular Data Registries (NCDR) said, "This project represents another example of how medical registries can help transform medicine. The ACC's registries and related provider networks support quality improvement programs for practitioners. For the first time, through our PINNACLE ambulatory office-based registry of the NCDR, we will be helping to solve the difficult problem of identifying physicians with patients who may be eligible for a clinical trial." The Full Research Report on Regeneron Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Celldex Therapeutics, Inc. Research Report
On December 26, 2013, Celldex Therapeutics, Inc.'s (Celldex) stock increased 4.30%, ending the day's trading session at $24.03. Over the previous three trading sessions, shares of Celldex increased 3.04%, compared to the Nasdaq Composite Index which increased 1.52% during the same period. The Full Research Report on Celldex Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Cubist Pharmaceuticals Inc. Research Report
On December 26, 2013, Cubist Pharmaceuticals Inc.'s (Cubist) stock declined 0.39%, ending the day's trading session at $66.94. Over the previous three trading sessions, shares of Cubist declined 0.04%, compared to the Nasdaq Composite Index which increased 1.52% during the same period. The Full Research Report on Cubist Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
MannKind Corp. Research Report
On December 26, 2013, MannKind Corp.'s (MannKind) stock increased 0.95%, ending the day's trading session at $5.30. Over the previous three trading sessions, shares of MannKind increased 5.79%, compared to the Nasdaq Composite Index which increased 1.52% during the same period. The Full Research Report on MannKind Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner